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Summary. The difference in the current cure rates between
adult and childhood acute lymphoblastic leukaemia (ALL)
may be caused by differences in drug resistance. Earlier
studies showed that in vitro cellular drug resistance is a
strong independent adverse risk factor in childhood ALL.
Knowledge about cellular drug resistance in adult ALL is
still limited. The present study compared the in vitro drug
resistance profiles of 23 adult ALL patients with that of 395
childhood ALL patients. The lymphoblasts were tested by
the MTT assay. The group of adult ALL samples was
significantly more resistant to cytosine arabinoside, l-
asparaginase, daunorubicin, dexamethasone and predniso-
lone. The resistance ratio (RR) was highest for prednisolone
(31´7-fold) followed by dexamethasone (6´9-fold), l-aspar-
aginase (6´1-fold), cytosine arabinoside (2´9-fold), daunor-
ubicin (2´5-fold) and vincristine (2´2-fold). Lymphoblasts
from adult patients were not more resistant to mercapto-
purine, thioguanine, 4-HOO-ifosfamide, mitoxantrone and
teniposide. There were no significant differences in drug
resistance between adult T-cell (T-) ALL (n  11) and adult
common/pre-B-cell (B-) ALL (n  10). Additionally, adult T-
ALL did not differ from childhood T-ALL (n  69). There
were significant differences between adult common/pre-B-
ALL and childhood common/pre-B-ALL (n  310) for
prednisolone (RR  302, P  0´008), dexamethasone
(RR  20´9, P  0´017) and daunorubicin (RR  2´7,
P  0´009). Lymphoblasts from adults proved to be
relatively resistant to drugs commonly used in therapy.
This might contribute to the difference in outcome between
children and adults with ALL.
Keywords: ALL, drug resistance, MTT assay, children,
adults.
Childhood leukaemias represent 8% of the leukaemias
affecting people of all ages (Pui, 1996). Acute lymphoblastic
leukaemia (ALL) constitutes about 80±85% of childhood
leukaemias, but only constitutes about 20% of acute
leukaemias in adults (Pui, 1996; Larson et al, 1998). The
rate of complete remission ranges is now 97±99% in
children and 75±90% in adults (Pui & Evans, 1998). Nearly
75% of children are currently cured compared with only
about 30% of adults with ALL (Pui & Evans, 1998).
Clinical features associated with poor prognosis are often
found in adult ALL patients. These include a higher fraction
[up to 62% in T-cell (T-) ALL] of patients presenting with a
high white blood cell count (more than 30  109/l), a high
proportion of lymphoblasts expressing myeloid antigens (in
about 25% of the cases), the absence of the CD10 antigen
(in half of the patients) and a slow induction of remission
with initial intensive therapies (Parentesis, 1997; Hoelzer,
1998; Larson et al, 1998). A majority of these ancillary
clinical characteristics are associated with the high-risk
immunophenotypic, karyotypic and molecular genetic
features. ALL in adults often shows unfavourable cytoge-
netic characteristics, as illustrated by the significantly
higher proportion of patients with the t(9;22) Philadelphia
(Ph) chromosome that, together with the expression of
p190 and p210 proteins, is associated with extremely poor
prognosis in 25±30% of adults and in 3±5% of children
(Laneuville et al, 1992; Parentesis, 1997). Hyperdiploidy, an
important favourable prognostic factor, is seen in approxi-
mately 25% of children and in only 5% of adults (Parentesis,
1997). TEL±AML1 fusion occurs in about 22% of childhood
ALL cases and in up to 3±4% in adult ALL (Rubnitz et al,
1999). Even for the same genetic subtypes of ALL, survival
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rates are lower in adults than in children (Pui & Evans,
1998). Adults younger than 30 years of age have a better
prognosis than those 30±59 years old, who, in turn, have a
better prognosis than patients who are 60 years of age or
older (Cortes & Kantarijan, 1995; Laport & Larson, 1997;
Chessels et al, 1998).
Poor prognosis of ALL in adults might be explained by
drug resistance mechanisms that are probably multifactor-
ial. Overexpression of transmembrane transporter mole-
cules, including P-glycoprotein or the multidrug resistance-
related protein, may be an important mechanism of drug
resistance in patients with high-risk ALL (Arceci, 1993).
Expression of P-glycoprotein has been associated with a
lower success of remission induction and a higher relapse
rate in adults with ALL (Goasguen et al, 1993). These
results, however, were not confirmed by others (Wattle et al,
1995). Significant differences were also observed in
methotrexate metabolism between cases of childhood and
adult ALL, and blasts from adults exhibit decreased
polyglutamylation and accumulation of methotrexate
(Goker et al, 1993). A study including a small number of
patients showed that lymphoblasts from adults with ALL
demonstrated a higher degree of in vitro corticosteroid
resistance than ALL blasts from children (Maung et al,
1995).
Several studies showed that cellular drug resistance is a
strong independent adverse risk factor in childhood ALL
(Pieters et al, 1991, 1998; Hongo et al, 1997; Kaspers et al,
1997,1998; Asselin et al, 1999). In addition, differences in
the above-mentioned factors such as age, immunopheno-
type and DNA ploidy are related to differences in drug
resistance (Pieters et al, 1993, 1998; Kaspers et al, 1995).
The knowledge about cellular drug resistance in adult ALL
is limited. In this study, we compared the in vitro drug
resistance profile for 14 drugs in 23 adults with ALL with
that of a group of 395 children.
PATIENTS AND METHODS
Patients and leukaemic cell samples. We tested 23 adults
with ALL and compared the results with our reference data
on the group of 395 childhood ALL. Bone marrow cells from
23 adults (12 men, 11 women) and 395 children (228
boys, 167 girls) with ALL at initial diagnosis were
successfully tested. The median age was 32 years (range
16±51 years) for adults and 5 years 2 months (range
2 months216 years) for children. Results of in vitro drug
resistance in 395 children have been published previously
(Pieters et al, 1998); here, they serve as a comparison group
for adults. Eleven adult patients had T-ALL, 10 patients had
common/pre-B-cell (B-) ALL and two patients had pro-B-
ALL [CD191, HLA-DR1, CD102, cytoplasmic m chain2
(cm2) and surface immunoglobulin2 (sIg2)]. Three hundred
and ten children had common/pre-B-ALL, 15 children had
pro-B-ALL and 69 children had T-ALL, in one case the
phenotype was unknown. Mature B-ALL cells characterized
by CD102/cm2/sIg1 were excluded from the study. T-
lineage ALL was characterized by the presence of two T-line
markers.
Cytogenetic data: in the group of children, 24 out of 76
(31´5%) tested subjects were TEL±AML1 positive, 39 out of
240 (16´2%) showed DNA index $ 1´16 and 33 out of 127
(26´0%) had hyperdiploidy $ 50 chromosomes. Respective
values for children with common/pre-B phenotype were
36´9%, 20´4% and 32´0%. In the group of adults, none of
six successfully tested patients showed hyperdiploidy, and
two out of 15 patients were positive for Ph chromosome,
including two out of six common ALL.
For 10 out of 23 adult patients, samples were tested after
cryopreservation. This procedure does not alter drug
sensitivity in childhood ALL (Kaspers et al, 1994a). A
comparison was made between the same specimen before
and after cryopreservation in eight adult patients for a total
number of 4±14 drugs for each patient. We did not observe
any changes in drug resistance before and after cryopre-
servation in two out of two precursor B-ALL patients and in
three out of six T-ALL patients (Spearman's rho  0´875,
P  0´001) However, in three T-ALL patients, the resistance
was higher after cryopreservation exceeding one dilution
step for prednisolone, vincristine and l-asparaginase (in all
three patients), etoposide (VP-16; in two patients), mitox-
antrone, daunorubicin and dexamethasone (in one patient).
For further analysis, results obtained on cryopreserved
samples of precursor-B-ALL only were used and there were
no T-ALL adult patients included in this study who were
tested from cryopreserved samples only. For calculation, the
priority was given to data obtained on fresh samples.
Separation of mononuclear cells from bone marrow (BM) and
peripheral blood (PB). Samples were diluted 1:1 or more with
Roswell Park Memorial Institute (RPMI)-1640 medium
(Dutch modification; Gibco, Uxbridge, UK). In case of the
presence of small clots, the sample of BM or PB was first
filtered through a cell strainer (70-mm nylon filter; Falcon,
Franklin Lakes, New Jersey, USA) using RPMI-1640 to rinse
off the strainer. Cells were separated on Ficoll gradient
(Lymphoprep density; 1´077 g/ml; Nyegaard, Oslo, Norway)
at 540 g for 20 min at room temperature. After centrifuga-
tion, cells were washed twice with RPMI-1640.
Frozen samples and thawing procedure. Samples of cryopre-
served leukaemic cells were used. Cells were frozen in 10%
DMSO (dimethylsulphoxide; Sigma Chemical, St. Louis, MO,
USA) in culture medium (or RPMI-1640) containing 20%
fetal calf serum (FCS) in a final volume of 2 ml and stored in
closed cryovials (Sterillin, Stone, UK) in liquid nitrogen. The
cryovials were rapidly thawed in a 378C waterbath and the
cell suspension was transferred to 18 ml RPMI-1640
containing 20% FCS. Isolation of cells was followed by two
wash steps (380 g, 10 min) in RPMI-1640 with 1% FCS.
The recovery of cells, viability and the red blood cell (RBC)/
white blood cell (WBC) ratio was calculated using 2%
trypan blue in phosphate-buffered saline (PBS) and a
cytospin stained with May±Grunwald±Giemsa (MGG) was
made to check the percentage of blasts. If the percentage of
blasts was less than 90%, the contamination with non-
malignant cells was diminished with purification by 30 min
incubation at 378C with one or more of immunomagnetic
polystyrene beads CD3, CD13, CD33, CD14, CD15 or
immunoglobulin (Ig)M (Dynabeads M-450; Dynal, Oslo,
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Norway) (Kaspers et al, 1994a). If the RBC/WBC ratio
. 0´5, erythrocytes were lysed with ammonium chloride,
followed by two wash steps.
Culture medium and culture suspension. The sample was
finally resuspended in culture medium containing RPMI-
1640, 20% heat-inactivated FCS, 2 mmol/l l-glutamine,
100 IU/ml penicillin, 100 mg/ml streptomycin, 0´125 mg/ml
amphotericin B, 200 mg/ml gentamicin (Flow Laboratories,
Irvine, UK), 5 mg/ml insulin, 5 mg/ml transferrin and 5 ng/
ml sodium selenite (Sigma). The cell concentration for the
MTT assay was finally adjusted to 2  106 vital cells/ml.
Drugs tested. Fourteen drugs were tested (Table I).
Dexamethasone and prednisolone were dissolved in saline,
6-thioguanine and 6-mercaptopurine in 0´1 N NaOH, 4-
HOO-ifosfamide in DMSO, daunorubicin and doxorubicin in
distilled water. The others were obtained as solutions ready
for use. All drugs were further diluted with RPMI-1640.
Serial dilutions were prepared and dispensed into micro-
culture plates. The concentrations of tested drugs are given
in Table I.
In vitro drug resistance assay. The assay conditions were
essentially the same as described previously (Kaspers et al,
1994a; Pieters et al, 1988,1989). Cell suspension (80 ml)
containing 2  106 vital cells/ml was incubated with each
drug concentration in 20 ml RPMI in duplicate wells of a
96-well round-bottomed microtitre plate (Greiner Labor-
technik, Alphen aan den Rijn, The Netherlands). Six wells
containing only cells in a drug-free medium served as
controls for cell survival, whereas four wells containing only
culture medium blanked the spectrophotometer. The outer
wells of the microculture plate were filled with RPMI-1640
only. Plates were then wrapped in cling film and incubated
for 4 d (96 h) at 378C in humidified air containing 5% CO2.
After 4 d, 50 mg (10 ml of a solution of 5 mg/ml) of 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyl tetrazoliumbromide (MTT;
Sigma) was added to each well (final concentration
0´45 mg/ml); plates were shaken and incubated for another
6 h at 378C. During exposure, yellow MTT was reduced into
purple formazan by viable, but not dead, cells. The formazan
crystals were dissolved with 100 ml of acidified (0´04 N HCl)
2-isopropanolol (Sigma) and the quantity of reduced product
was measured by an enzyme-linked immunosorbent assay
(ELISA) EL-312 microplate spectrophotometer at 562 nm
(BioKinetics Reader, Bio-Tek Instruments, Winooski, VT,
USA). The optical density (OD) at 562 nm is linearly related
to the number of viable cells (Kaspers et al, 1994a). Cytospin
slides from control wells, stained with MGG, were used to
determine the percentage of blasts after 96 h incubation.
Samples with more than 70% leukaemic cells in the control
wells without drugs after 4 d of culture and with an OD
greater than 0´050 arbitrary units (adjusted for blank
values) were suitable for evaluation (Kaspers et al, 1995,
1997, 1998). The leukaemic cell survival was calculated by
the equation: (OD drug well/mean OD control
wells)  100%. The OD of both control and tested wells
were adjusted by OD of blank wells. The LC50, the
concentration of drugs that was lethal to 50% of the cells
(in IU/ml for l-asparaginase and in mg/ml for other drugs),
was used as a measure for the in vitro drug cytotoxicity in
each sample (Kaspers et al, 1994a; Pieters et al, 1988,
1989).
Statistics. The non-parametric Wilcoxon matched pairs
signed ranks and Spearman's rank correlation tests were
used to compare LC50 values for fresh and cryopreserved
samples. The Mann±Whitney U-test was used to compare
drug resistance between groups. All tests were used for two-
tailed testing at a level of significance of 0´05. Statistical
calculations were performed with the program SPSS for
Windows.
RESULTS
The group of adult ALL samples showed higher LC50 values
for all 14 drugs than the childhood ALL samples (Table II).
For cytosine arabinoside, l-asparaginase, daunorubicin,
dexamethasone and prednisolone, the differences were
statistically significantly different, and for doxorubicin,
idarubicin and vepesid the results almost reached signifi-
cance. The relative resistance ratios (RR) were calculated for
each drug by dividing the median LC50 value of the adult
ALL group by the median LC50 value of the child ALL group.
The highest RR was found for prednisolone (31´7-fold)
followed by dexamethasone (6´9-fold), l-asparaginase (6´1-
fold), cytosine arabinoside (2´9-fold), daunorubicin (2´5-
fold), vincristine (2´2-fold) and idarubicin (2´0-fold),
although for the last two drugs significance was not
reached. Lymphoblasts from adult patients did not differ
significantly in sensitivity from childhood ALL for mercap-
topurine, thioguanine, ifosfamide, mitoxantrone and tenipo-
side.
Eleven adult patients were under 30 years and 12 were
over 30 years of age. The resistance profiles of these two
groups did not significantly differ with the exception of
doxorubicin (RR  1´49, P  0´049), indicating that
patients over 30 years were more resistant to this drug.
We also compared drug resistance profiles according to
Table I. Concentration ranges of the drugs tested.
Drug
Concentration
range (mg/ml)
Prednisolone (Prednisolone, Brocacef) 0´08±250
Dexamethasone (Dexamethasone, Brocacef) 0´0002±6
Vincristine (Oncovin, Lilly) 0´049±50
l-Asparaginase (Crasnitin, Bayer) 0´0032±10*
Daunorubicin (Cerubidine, Rhone-Poulenc) 0´002±2
Doxorubicin (Adriblastina, Farmitalia) 0´0078±8
Idarubicin (Zavedos, Farmitalia) 0´002±2
Mitoxantrone (Novantrone, Lederle) 0´00121
Cytosine arabinoside (Cytosar, Upjohn) 0´0024±2´5
6-Mercaptopurine (Sigma, no. M7000) 15´6±500
6-Thioguanine (Sigma, no. A4882) 1´56250
Vepesid (Vepesid, Bristol-Myers) 0´049±50
Teniposide (Vumon, Bristol-Myers) 0´003±8
4-HOO-Ifosfamide (Asta Medica) 0´1±100
*IU/ml.
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immunophenotype of blasts. There were no significant
differences in drug resistance between adult T-ALL (n  11)
and adult common/pre-B-ALL (n  10). Adult T-ALL also
did not differ significantly in drug resistance from childhood
T-ALL (n  69). There were differences between adult
common/pre-B-ALL and childhood common/pre-B-ALL
(n  310) for prednisolone (RR  302, P  0´008), dex-
amethasone (RR  20´9, P  0´017) and daunorubicin
(RR  2´77, P  0´009) (Table III).
DISCUSSION
Failure to cure leukaemia is probably due to the failure of
eradicating the leukaemic clone. Mechanisms of drug
resistance acting before the drug reaches its target
(pharmacological resistance) and after the drug interacts
with its target (cellular resistance) are gaining greater
importance in understanding treatment failures ( Veerman
et al, 1994; Minden et al, 1996). The results of the present in
vitro study suggest that acute lymphoblastic leukaemia
(ALL) in adults is a highly drug-resistant disease in
comparison with childhood ALL.
Maung et al (1995), in a similar study including 16
adults, 32 children and six drugs, showed that lymphoblasts
from adults demonstrated a significantly higher degree of in
vitro resistance to prednisolone than those from children. He
Table III. Drug sensitivity profile: adult common/preB-ALL vs. childhood common/pre-B-ALL.
Median LC50 (number of patients)
RR P-valueAdults Children
Prednisolone 145 (10) 0´48 (273) 302 0´008
Dexamethasone 1´40 (9) 0´067 (201) 20´9 0´017
Vincristine 0´44 (9) 0´67 (267) 0´65 0´257
l-Asparaginase 0´36 (9) 0´12 (255) 3´00 0´392
Daunorubicin 0´25 (10) 0´09 (282) 2´77 0´009
Doxorubicin 0´43 (9) 0´29 (175) 1´48 0´105
Idarubicin 0´085 (9) 0´030 (108) 2´83 0´118
Mitoxantrone 0´026 (10) 0´048 (182) 0´54 0´886
Cytosine arabinoside 0´44 (10) 0´44 (225) 1´00 0´945
6-Mercaptopurine 130 (8) 91 (230) 1´42 0´407
6-Thioguanine 5´72 (9) 5´84 (242) 0´97 0´749
Vepesid 2´22 (10) 1´36 (82) 1´63 0´093
Teniposide 0´29 (9) 0´25 (189) 1´16 0´398
4-HOO-Ifosfamide 2´76 (7) 2´86 (124) 0´96 0´976
RR, median LC50 (adult)/median LC50 (children); LC50, values given as IU/ml for l-asparaginase and mg/
ml for other drugs; P-value, Mann±Whitney U-test.
Table II. Drug sensitivity profile: adult initial ALL vs. childhood initial ALL.
Median LC50 (25±75 percentiles, number of patients)
RR P-valueAdults Children
Prednisolone 40´0 (0´85 to . 250, 23) 1´26 (0´27±89´03, 350) 31´7 0´011
Dexamethasone 0´55 (0´11 to . 6, 20) 0´08 (0´028±3´54, 268) 6´9 0´008
Vincristine 1´67 (0´3±17´33, 21) 0´75 (0´3±2´95, 345) 2´2 0´331
l-Asparaginase 1´28 (0´13 to . 10, 21) 0´21 (0´0025±1´22, 329) 6´1 0´014
Daunorubicin 0´25 (0´1±0´54, 22) 0´10 (0´067±0´22, 359) 2´5 0´001
Doxorubicin 0´41 (0´25±0´93, 20) 0´31 (0´16±0´47, 226) 1´3 0´057
Idarubicin 0´08 (0´036±0´092, 19) 0´04 (0´02±0´09, 134) 2´0 0´086
Mitoxantrone 0´053 (0´011±0´23, 21) 0´049 (0´019±0´11, 234) 1´08 0´754
Cytosine arabinoside 1´39 (0´28 to . 2´5, 23) 0´47 (0´21±1´14, 296) 2´9 0´023
6-Mercaptopurine 107 (66´96±166´67, 19) 102 (50±250, 299) 1´05 0´718
6-Thioguanine 6´99 (4´3±10´82, 21) 6´00 (3´8±9´15, 311) 1´16 0´359
Vepesid 2´23 (0´88±7´57, 22) 1´45 (0´65±2´53, 107) 1´5 0´081
Teniposide 0´30 (0´2±1´42, 19) 0´27 (0´18±0´61, 252) 1´1 0´193
4-HOO-Ifosfamide 3´58 (1´16±5´25, 17) 3´24 (1´45±4´95, 167) 1´1 0´945
RR, median LC50 (adult)/median LC50 (children); LC50, values given as IU/ml for l-asparaginase and mg/ml for other drugs;
P-value, Mann±Whitney U-test.
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concluded that cellular glucocorticoid resistance may be a
fundamental difference between adult and childhood ALL
that may be caused by different biological aspects and may
also explain the difference in prognosis. Our study confirms
the problem of glucocorticoid resistance in adult ALL. In
addition, we demonstrated resistance to cytosine arabino-
side, l-asparaginase, daunorubicin and possibly other
anthracyclines. On the other hand, adult ALL cells seem
to be as sensitive as childhood ALL cells to 4-HOO-
ifosfamide, mitoxantrone, teniposide and thiopurines.
Analysis of phenotypes suggests that sensitivity of adult T-
ALL is similar to adult common/pre-B-ALL and to childhood
T-ALL, but adult common/pre-B-ALL is much more
resistant than common/pre-B-ALL in children. This is in
agreement with the fact that common/pre-B-ALL is not a
favourable phenotype in adults. As prognosis in ALL
decreases with increased age (Pui, 1996), we analysed the
influence of age on cellular drug resistance within the adult
group. Apart from doxorubicin, we did not find any
statistically significant differences between age groups
within adult patients, although patients over 30 years had
high resistance ratios for glucocorticoids and mitoxantrone.
This is in accordance with our earlier findings that cells
from children aged . 10 years are more resistant to
glucocorticoids than cells from children , 10 years of age
(Pieters et al, 1998). In general, it is difficult to draw any
conclusion, as the number of adult patients in our study is
not high. As elderly patients tolerate treatment poorly
(Chessells et al, 1998), pharmacokinetics and side-effects of
chemotherapy may play an important role in the poorer
outcome of elderly patients (Hoelzer, 1993a,b). Also, a
higher frequency of adverse biological features, for example
the incidence of Ph chromosome, may account for the poor
treatment results in adults. However, predictive value of
primary genetic abnormalities is not very high (Pui & Evans,
1998).
It has been hypothesized that `good prognosis' ALL arises
in lymphoid cells that are naturally `poised' for apoptotic
death and that chemotherapy is thus able to trigger
programmed leukaemic cell death efficiently in these
patients (Campana et al, 1993; Greaves, 1993; Fisher,
1994). Drug resistance in adult ALL may be associated with
activation of antiapoptotic pathways as a consequence of
aberrant growth signalling, resulting from the bypassing of
normal growth factor signalling pathways in malignant
cells (Baserga, 1994). Glucocorticoids, cytosine arabinoside
and anthracyclines are thought to act on the proapoptotic
pathway (Alnemri et al, 1992; Kaspers et al, 1994b; Den
Boer et al, 1998; Savasan et al, 1998). Probably, the other
drugs also have a proapoptotic mechanism of action, and
apoptosis resistance may play a role in the resistance to
therapy.
In ALL, the first goal of therapy is to induce complete
remission with restoration of normal haematopoiesis. The
induction regimen invariably includes a glucocorticoid
(prednisolone or dexamethasone) and vincristine, as well
as asparaginase and/or an anthracycline (Copelan &
McGuire, 1995; Cortes & Kantarijan, 1995; Laport &
Larson, 1997; Chessells et al, 1998). The therapy for ALL
in adults has met with irregular success, often despite the
use of treatment regimens similar to those used in childhood
(Copelan & McGuire, 1995). Currently, there is no subgroup
of ALL patients in which standard chemotherapy can be
described as adequate and improved treatment is needed for
all groups of patients (Linker, 1997). Leukaemic cells from
adults proved to be highly resistant to drugs commonly used
in induction therapy.
In conclusion, we have found that adults with ALL were
more drug resistant than children. This might contribute to
the difference in outcome between those age groups of
patients with acute lymphoblastic leukaemia. However, the
extent of resistance varied between individual drugs. These
data could support the rational design of new treatment
protocols.
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